Reports
Sale
Global Allergy Immunotherapy Market Share, Size, Analysis, Report: By Treatment Type: Subcutaneous Immunotherapy (SCIT), Specific Immunotherapy (SIT), Sublingual Immunotherapy (SLIT); By Allergan Type: Pollen Allergies, Food Allergies, Others; By Treatment Channel; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Global Allergy Immunotherapy Market Outlook
The global allergy immunotherapy market size attained a value of USD 2.24 billion in 2023 driven highly by increase in prevalence of allergic diseases. The market is anticipated to grow at a CAGR of 9.6% during the forecast period of 2024-2032 to attain a value of USD 5.10 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Market Likely to be Driven by Increase in Prevalence of Allergic Diseases
In the USA, over 7.5% of the people eighteen years of age or above experience allergic rhinitis or hay fever. A significant percentage of children also suffers from hay fever. Allergic rhinitis affects ten to thirty percent of the population across the globe. Further, over five percent of children across the world experience some kind of food allergy. Globally, increase in prevalence of allergic diseases has continued in the industrialized world for over fifty years. Such prevalence of allergic conditions is expected to drive the global allergy immunotherapy market. Allergies can have a significant affect on health and quality of life. Allergen immunotherapy can provide long-lasting therapeutic relief to people suffering from environmental allergies. Allergen immunotherapy (also called allergy shots) refers to a type of long-term treatment that reduces symptoms for individuals experiencing allergic rhinitis, allergic asthma, conjunctivitis (eye allergy) or stinging insect allergy. Allergy shots reduce sensitivity to allergens and usually offer lasting relief from allergy symptoms even after the treatment is stopped, making it an economical and beneficial treatment approach for several people. Immunotherapy is a preventive treatment for allergic reactions to substances like grass pollens, house dust mites and bee venom; it also decreases inflammation that characterizes rhinitis and asthma.
Adults as well as children may receive allergy shots, however, the treatment is not usually suggested for children below age five. When considering allergen immunotherapy for an older adult, medical conditions including cardiac disease must be taken into consideration. Important considerations include: duration of allergy season and severity of symptoms; how well medications and environmental controls are helping allergy symptoms; the patient’s desire to avoid long-term medication use; time available for treatment; cost. Food allergies are not treated through allergy shots.
Allergen Immunotherapy has been Shown to Reduce Symptoms of Several Allergies
Allergy shots act like a vaccine; the body responds to injected amounts of a specific allergen, administered in gradually increasing doses, by developing immunity or tolerance to the allergen. The gradual increases of the allergen enable the immune system to become less sensitive to the substance, possibly by causing production of a “blocking” antibody which decreases the symptoms of allergy when the substance is encountered in the future. In the build-up phase, injections are administered with increasing amounts of the allergens one to two times per week; the phase may last three to six months. The maintenance phase commences once the effective dose is reached; the effective dose depends on allergen sensitivity levels and the person’s response to the build-up phase. During the maintenance phase, the duration of time between shots might become longer (two to four weeks).
Allergen immunotherapy has been shown to reduce symptoms of several allergies; it may also prevent the development of new allergies. In children, it could prevent the development of allergic disease from allergic rhinitis to asthma. The relief provided by allergen immunotherapy is expected to boost the global allergy immunotherapy market.
Indications for allergen immunotherapy include moderate-to-severe allergic rhinitis; allergic asthma; allergic conjunctivitis; allergic rhino-conjunctivitis; atopic dermatitis; immune-mediated and IgE-mediated food allergy; insect allergy that causes significant local reaction and anaphylaxis.
Developments in the Domain Likely to Boost Market Growth
In 2020, it was reported that researchers from the University of Tsukuba had developed a novel system that enabled the mass production of the major birch pollen allergen Bet v 1 in plant leaves in just a few days. A study published in Frontiers in Plant Science showed that their system not only produced large amounts of Bet v 1, but the purified protein was also highly reactive towards the IgE antibodies in sera from individuals with birch pollen allergy. Such developments, along with several others in the domain, are expected to boost the global allergy immunotherapy market.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Segmentation
By allergy, the market is segmented into:
- Allergic Asthma
- Cat Allergy
- Allergic Rhinitis
- Peanut Allergy
- Others
By treatment, the market is divided into:
- Sublingual Immunotherapy
- Subcutaneous Immunotherapy (SCIT)
- Specific Immunotherapy (SIT)
By distribution channel, the market is classified into:
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
By region, the market is segmented into:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Key Industry Players in the Market
The report presents a detailed analysis of the following key players in the global Allergy Immunotherapy market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- ASIT Biotech
- Circassia Group PLC
- Adamis Pharmaceuticals Corporation
- Merck KGaA
- Stallergenes Greer Ltd
- Allergy Therapeutics PLC
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Allergan Type |
|
| Breakup by Treatment Channel |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Allergy Diseases Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Allergy Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Allergy Epidemiology (2016-2031)
5.3 Europe Allergy Epidemiology (2016-2031)
5.4 Asia-Pacific Allergy Epidemiology (2016-2031)
5.5 Latin America Allergy Epidemiology (2016-2031)
5.6 Middle East & Africa Allergy Epidemiology (2016-2031)
6 Global Allergy Immunotherapy Market Overview
6.1 Global Allergy Immunotherapy Market Historical Value (2017-2023)
6.2 Global Allergy Immunotherapy Market Forecast Value (2024-2032)
7 Global Allergy Immunotherapy Market Landscape
7.1 Global Allergy immunotherapy: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Allergy Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Allergan Type
7.2.3 Analysis by Distribution Channel
8 Allergy Immunotherapy Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Allergy Immunotherapy Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Allergy Immunotherapy Market Segmentation
11.1 Global Allergy Immunotherapy Market by Treatment Type
11.1.1 Market Overview
11.1.2 Subcutaneous Immunotherapy (SCIT)
11.1.3 Specific Immunotherapy (SIT)
11.1.4 Sublingual Immunotherapy (SLIT)
11.1.4.1 Sublingual Drops
11.1.4.2 Sublingual Tablets
11.2 Global Allergy Immunotherapy Market by Allergan Type
11.2.1 Market Overview
11.2.2 Pollen Allergies
11.2.2.1 Grass Pollen
11.2.2.2 Tree Pollen
11.2.2.3 Weed Pollen
11.2.3 Food Allergies
11.2.3.1 Peanut Allergies
11.2.3.2 Tree Nut Allergies
11.2.3.3 Shellfish Allergies
11.2.3.4 Fish Allergies
11.2.3.5 Egg Allergies
11.2.3.6 Milk Allergies
11.2.3.7 Soy Allergies
11.2.3.8 Wheat Allergies
11.2.3.9 Others
11.2.4 Dust Mite Allergies
11.2.5 Mold Allergies
11.2.6 Animal Dander Allergies
11.2.7 Insect Venom Allergies
11.3 Global Allergy Immunotherapy Market by Treatment Channel
11.3.1 Market Overview
11.3.2 Public
11.3.3 Private
11.4 Global Allergy Immunotherapy Market by Distribution Channel
11.4.1 Market Overview
11.4.2 Direct Tenders
11.4.3 Retail Sales
11.4.4 Others
11.5 Global Allergy Immunotherapy Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Allergy Immunotherapy Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Allergy Immunotherapy Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Allergy Immunotherapy Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Allergy Immunotherapy Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Allergy Immunotherapy Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 ALK-Abelló A/S
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Allergy Therapeutics
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Aimmune Therapeutics
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Stallergenes Greer
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Merck Group
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 HAL Allergy Group
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 DBV Technologies
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Biomay AG
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Anergis SA
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Circassia Pharmaceuticals
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Laboratorios LETI
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 HollisterStier Allergy
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
24 Allergy Immunotherapy Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
In 2023, the global market of Allergy Immunotherapy attained a value of USD 2.24 billion.
The market is anticipated to grow at a CAGR of 9.6% during the forecast period of 2024-2032 to reach a value of USD 5.10 billion by 2032.
The major drivers of the market include the climate change, standardisation of dosage, strong pipeline of immunotherapy products, and increased consumption of alcohol.
The rising prevalence of allergic disorders and increasing air pollution, both indoors and outdoors, are the key industry trends propelling the market's growth.
For some allergies, success rates have been shown to be as high as 80-90%. It is a lengthy procedure; if therapy is effective, it should be continued for three to five years after considerable improvement is seen.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major allergies studied in the market are allergic asthma, cat allergy, allergic rhinitis, and peanut allergy, among others.
Based on treatment, the market is classified into sublingual immunotherapy, subcutaneous immunotherapy (SCIT), and specific immunotherapy (SIT).
The several distribution channels of the market are retail pharmacy, hospital pharmacy, and online pharmacy.
Treatment with maintenance immunotherapy typically lasts for about 3 to 5 years. The length of allergen immunotherapy varies from person to person, since some people get long-lasting remission of their allergy symptoms, while others may experience relapse after stopping immunotherapy.
The major players in the industry are ASIT Biotech, Circassia Group PLC, Adamis Pharmaceuticals Corporation, Merck KGaA, Stallergenes Greer Ltd, and Allergy Therapeutics PLC, among others.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER